Sansure Biotech Inc. (SHA:688289)
China flag China · Delayed Price · Currency is CNY
16.08
+0.18 (1.13%)
Sep 14, 2026, 3:00 PM CST

Sansure Biotech Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,5821,6161,424991.16,3044,342
Other Revenue
25.5725.5734.1416.02146.58172.86
1,6071,6421,4581,0076,4504,515
Revenue Growth
-0.15%12.58%44.78%-84.39%42.88%-5.22%
Cost of Revenue
427.43420.23279.71280.962,9121,283
Gross Profit
1,1801,2211,178726.153,5383,232
Selling, General & Admin
860.62823.38749.79547.37939.48488.21
Research & Development
227.13226.44276.64194.81331.2186.84
Other Operating Expenses
9.615.8510.960.127.3112.48
Operating Expenses
1,1291,0871,051747.231,344706.01
Operating Income
50.65133.85127.26-21.082,1942,526
Interest Expense
-23.29-23.29-18.4-2.41-2.09-0.83
Interest & Investment Income
86.8286.8297.53308.4148.3532.53
Currency Exchange Gain (Loss)
1.721.726.854.315.04-42.25
Other Non Operating Income (Expenses)
-16.1-1.36-17.1-9.15-7.94-1.61
EBT Excluding Unusual Items
99.8197.74196.14280.082,2372,513
Impairment of Goodwill
-1.94-1.94---1.44-
Gain (Loss) on Sale of Investments
35.58-6.66-20.4461.8479.2481.01
Gain (Loss) on Sale of Assets
-13.75-5.36-4.21-7.21-5.470.41
Asset Writedown
-17.12-6.49-1.25--15.1-
Other Unusual Items
-2.2-2.290.3675.7621.321.37
Pretax Income
100.37175.08260.61410.482,3162,616
Income Tax Expense
7.8721.1634.3462.31379.21373.68
Earnings From Continuing Operations
92.49153.92226.27348.171,9372,243
Minority Interest in Earnings
41.7445.0149.3215.550.090.17
Net Income
134.24198.94275.6363.721,9372,243
Net Income to Common
134.24198.94275.6363.721,9372,243
Net Income Growth
-52.33%-27.82%-24.23%-81.22%-13.64%-14.29%
Shares Outstanding (Basic)
583585586587585589
Shares Outstanding (Diluted)
583585586587585589
Shares Change
-0.67%-0.22%-0.05%0.26%-0.59%6.55%
EPS (Basic)
0.230.340.470.623.313.81
EPS (Diluted)
0.230.340.470.623.313.81
EPS Growth
-52.01%-27.66%-24.19%-81.27%-13.12%-19.56%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-58.53-185.81-146.66-347.812,0001,504
Free Cash Flow Per Share
-0.10-0.32-0.25-0.593.422.56
Dividend Per Share
0.5230.5230.5250.4621.2980.760
Dividend Growth
90.18%-0.38%13.59%-64.39%70.77%0%
Gross Margin
73.41%74.40%80.82%72.10%54.85%71.58%
Operating Margin
3.15%8.15%8.73%-2.09%34.01%55.94%
Profit Margin
8.35%12.12%18.90%36.12%30.03%49.68%
Free Cash Flow Margin
-3.64%-11.32%-10.06%-34.53%31.01%33.32%
EBITDA
276.71335.46269.7179.82,2692,571
EBITDA Margin
17.22%20.44%18.50%7.92%35.18%56.96%
D&A For EBITDA
226.06201.61142.45100.8875.4745.89
EBIT
50.65133.85127.26-21.082,1942,526
EBIT Margin
3.15%8.15%8.73%-2.09%34.01%55.94%
Effective Tax Rate
7.85%12.08%13.18%15.18%16.37%14.28%
Revenue as Reported
1,6421,6421,4581,0076,4504,515
Advertising Expenses
-58.7468.0726.2836.3632.38